|
Effective use of biomarkers at each stage of R&D can improve decision-making, increase clinical trial success rates and productivity and allow earlier stop/go decisions to be made, eliminating waste of resources, which can otherwise be re-deployed.
Companies taking advantage of and making best use of biomarkers in R&D are reaping the rewards of gaining the competitive edge.
Designed to focus specifically on oncology, The SMi Group's Cancer Biomarkers Conference is an excellent opportunity for you to learn from industry leaders about how they are applying biomarkers to expedite cancer detection, drug discovery and development.
Our excellent panel of speakers includes:
- Andreas Strauss, Head PDx Portfolio Management, Biomarker Program Oncology, Roche Diagnostics GmbH.
- Dr Stephen Barnhill, Chairman & Chief Executive Officer, Health Discovery Corporation
- Dr Herbert Fritsche, Professor, Laboratory Medicine and Chief, Clinical Chemistry Section, MD Anderson Cancer Center & Chairman, Scientific Advisory Board, Health Discovery Corporation
- Dr Mark Rolfe, Vice President, Discovery Oncology, Millennium Pharmaceuticals
- Dr Hans Winkler, Senior Director, Functional Genomics, Johnson & Johnson
- Dr Peter Shaw, Senior Director, Clinical Oncology, Merck Research Laboratories
- Professor Andrew Hughes, Worldwide Clinical Director, Discovery Medicine, AstraZeneca Oncology
- Dr Philip Murphy, Director, Clinical Research & Development, Pfizer
- Dr Sridhar K Rabindran, Associate Director, Oncology Research, Wyeth
- Dr Paul McSheehy, Senior Research Investigator & Lab Head, Oncology Research, Novartis Pharma
- Dr Hans-Juergen Arens, Manager, Medical & Scientific Development, Europe, Middle East & Africa, Abbott
The programme will be led by a panel of international experts, including:
By attending, you will benefit from hearing about: - UNRAVELLING the complexities of cancer
- PREDICTIVE response markers in oncology
- USING biomarkers as a novel tool in the diagnosis and treatment of cancer
- WHERE the bottle necks lie in technology applications
- TISSUE ANALYSIS and the development of pharmacodynamic end points for new cancer drugs
- OVERCOMING obstacles in developing clinically useful biomarker tests
- HOW cancer biomarkers can aid the decision-making process
- VALIDATING your cancer biomarker
- AND much more!
|
Events Home Page
